Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Malaria FalciparumMalaria InfectionMalaria Transmission
Interventions
BIOLOGICAL

NF54/iGP3

Mosquito-generated sporozoites of the genetically modified, inducible gametocyte-producing parasite line NF54/iGP3, created via CRISPR/Cas9 genetic engineering of the parental wildtype strain Plasmodium falciparum (Pf) NF54 to contain a trimethoprim (TMP)-inducible copy of the Pf gdv1 gene in the dispensable Pf cg6 locus.

Trial Locations (1)

3002

Doherty Clinical Trials, Melbourne

All Listed Sponsors
collaborator

Walter and Eliza Hall Institute of Medical Research

OTHER

collaborator

Swiss Tropical & Public Health Institute

OTHER

collaborator

QIMR Berghofer Medical Research Institute

OTHER

lead

University of Melbourne

OTHER